Emerging Lessons From The Drug Effectiveness Review Project
Open Access
- 1 January 2006
- journal article
- Published by Health Affairs Publishing, LLC in Health Affairs
- Vol. 25 (4) , W262-W271
Abstract
The Drug Effectiveness Review Project (DERP) is an alliance of fifteen states and two private organizations, which have pooled resources to synthesize and judge clinical evidence for drug-class reviews. The experience shines a bright light on challenges involved in implementing an evidence-based medicine process to inform drug formulary decisions: When should evidence reviewers accept surrogate markers and assume therapeutic class effects? How open and participatory should review procedures be? Should reviewers consider cost-effectiveness information? What is the appropriate role of the public sector in judging evidence? The DERP illustrates that attempts to undertake evidence-based reviews, apart from the methods themselves, which continue to evolve, involve questions of organization, process, and leadership.Keywords
This publication has 13 references indexed in Scilit:
- Medicare and Cost-Effectiveness AnalysisNew England Journal of Medicine, 2005
- States’ Control Of Prescription Drug Spending: A Heterogeneous ApproachHealth Affairs, 2005
- Evidence Of Evidence-Based Health Policy: The Politics Of Systematic Reviews In Coverage DecisionsHealth Affairs, 2005
- Making Policy When The Evidence Is In DisputeHealth Affairs, 2005
- Evidence Based? Caveat Emptor!Health Affairs, 2005
- When Is Evidence Sufficient?Health Affairs, 2005
- Using Evidence Reports: Progress And Challenges In Evidence-Based Decision MakingHealth Affairs, 2005
- Surrogate Endpoints And FDA’s Accelerated Approval ProcessHealth Affairs, 2005
- Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic reviewJournal of Pain and Symptom Management, 2004
- The Road To Meaningful Reform: A Conversation With Oregon’s John KitzhaberHealth Affairs, 2003